Mehmet Sıddık DİLEK, Abdullah KARAKUŞ, Vehbi DEMİRCAN, Selahattin TEKEŞ, Mehmet Orhan AYYILDIZ
Acta Haematologica Oncologica Turcica - 2026;59(2):126-131
Aim: This study aimed to examine the demographic characteristics, disease stages, 17-deletion status, complications, treatment approaches, and survival data of 308 chronic lymphocytic leukemia (CLL) patients followed in the Department of Hematology at Dicle University. Methods: A retrospective analysis was conducted on 308 patients diagnosed with CLL between January 2015 and December 2019. Data were compiled from patient records, including demographic information, complete blood counts, lactate dehydrogenase levels, lymphocyte counts, flow cytometry results, cytogenetic analysis (17p deletion), and imaging findings. Patients were classified according to the Rai and Binet staging systems, and their treatment protocols and disease complications were examined. Results: In a retrospective analysis of 308 CLL patients, 61.7% were male, 38.3% were female, and the median age was 63 (28-86). Of the 170 patients studied for 17p deletion, 15.3% were found to be positive for 17p deletion. When patients were staged according to Rai, 8.4% were stage 0, 42.2% were stage I, 31.5% were stage II, 12.3% were stage III, and 5.5% were stage IV. According to the Binet staging, 29.5% of the patients were classified as stage A, 57.1% were classified as stage B, and 13.3% were classified as stage C. Secondary immunodeficiency was observed in 18.8% of the patients, autoimmune hemolytic anemia in 10.1%, and Richter transformation in 2.9%. One hundred ninety-nine patients (64.6%) received treatment, while 109 (35.4%) did not. During a median follow-up of 68.1 months, 38.3% of patients died. Patients with more advanced Rai and Binet stages had significantly shorter survival times. The median overall survival of patients with a positive 17p deletion was 83.4 months, while that of patients with a negative 17p deletion was 116 months (p=0.015). Conclusion: The 17p deletion is associated with poor prognosis in CLL and is an important marker for guiding treatment and monitoring survival. The patient profile, stage, and treatment data from this regional study can contribute to the literature and guide the development of personalized approaches.
